VIVANI MED.INC. NEW O.N. (U5P) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VIVANI MED.INC. NEW O.N. (U5P) has a cash flow conversion efficiency ratio of -0.427x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.72 Million ≈ $-7.86 Million USD) by net assets (€15.73 Million ≈ $18.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VIVANI MED.INC. NEW O.N. balance sheet independence to measure how much of total assets are equity-financed.
VIVANI MED.INC. NEW O.N. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how VIVANI MED.INC. NEW O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore VIVANI MED.INC. NEW O.N. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
VIVANI MED.INC. NEW O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VIVANI MED.INC. NEW O.N. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vera Bradley Inc
NASDAQ:VRA
|
-0.042x |
|
Yusin Holding Corp
TW:4557
|
0.016x |
|
Canterbury Park Holding Corporation
NASDAQ:CPHC
|
0.048x |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
-0.202x |
|
Energy Transition Minerals Ltd
AU:ETM
|
-0.101x |
|
Strix Group Plc
F:SG9
|
N/A |
|
Integra Indocabinet Tbk PT
JK:WOOD
|
0.013x |
|
CSP Inc
NASDAQ:CSPI
|
-0.011x |
Annual Cash Flow Conversion Efficiency for VIVANI MED.INC. NEW O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of VIVANI MED.INC. NEW O.N. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see VIVANI MED.INC. NEW O.N. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €15.73 Million ≈ $18.39 Million |
€-24.32 Million ≈ $-28.43 Million |
-1.546x | -30.99% |
| 2024-12-31 | €17.61 Million ≈ $20.59 Million |
€-20.79 Million ≈ $-24.30 Million |
-1.180x | -3.40% |
| 2023-12-31 | €20.76 Million ≈ $24.27 Million |
€-23.70 Million ≈ $-27.71 Million |
-1.142x | -169.22% |
| 2022-12-31 | €44.31 Million ≈ $51.80 Million |
€-18.79 Million ≈ $-21.96 Million |
-0.424x | +90.46% |
| 2021-12-31 | €2.46 Million ≈ $2.88 Million |
€-10.95 Million ≈ $-12.80 Million |
-4.443x | -- |
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more